Direkt zum Inhalt
Merck
Alle Fotos(1)

Wichtige Dokumente

Gesamtdokumentation anzeigen

EPS002

Sigma-Aldrich

MS-275

A HDAC1 and HDAC3 inhibitor

Synonym(e):

MS-275 (Entinostat, SNDX-275), 3-pyridinylmethyl [[4-[[(2-aminophenyl)amino]carbonyl]phenyl]methyl]carbamate, N-(2-Aminophenyl)-4-[N-(pyridine-3ylmethoxycarbonyl)aminomethyl]benzamide

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise
Alle Fotos(1)

About This Item

Empirische Formel (Hill-System):
C21H20N4O3
CAS-Nummer:
209783-80-2
Molekulargewicht:
376.41
MDL-Nummer:
MFCD03453552
UNSPSC-Code:
12352200
PubChem Substanz-ID:
329799578
NACRES:
NA.41

Assay

≥99%

Löslichkeit

DMSO: 38 mg/mL

Lagertemp.

−20°C

SMILES String

Nc1ccccc1NC(=O)c2ccc(CNC(=O)OCc3cccnc3)cc2

InChI

1S/C21H20N4O3/c22-18-5-1-2-6-19(18)25-20(26)17-9-7-15(8-10-17)13-24-21(27)28-14-16-4-3-11-23-12-16/h1-12H,13-14,22H2,(H,24,27)(H,25,26)

InChIKey

INVTYAOGFAGBOE-UHFFFAOYSA-N

Angaben zum Gen

human ... HDAC1(3065) , HDAC10(83933) , HDAC11(79885) , HDAC2(3066) , HDAC3(8841) , HDAC4(9759) , HDAC5(10014) , HDAC6(10013) , HDAC7(51564) , HDAC8(55869) , HDAC9(9734)

Suchen Sie nach ähnlichen Produkten? Aufrufen Leitfaden zum Produktvergleich

Allgemeine Beschreibung

Preferentially inhibits HDAC1 (IC50=300 nM) over HDAC3 (IC50=8 μM). Has no inhibitory activity towards HDAC8 (IC50>100 μM).

Anwendung

MS-275 has been used as a histone deacetylase-1 inhibitor.

Biochem./physiol. Wirkung

HDAC inhibitor; antiproliferative.

Piktogramme

Skull and crossbonesHealth hazard
GHS06,GHS08

Signalwort

Danger

H-Sätze

H301,H360

Gefahreneinstufungen

Acute Tox. 3 Oral - Repr. 1A

Lagerklassenschlüssel

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable

Analysenzertifikate (COA)

Suchen Sie nach Analysenzertifikate (COA), indem Sie die Lot-/Chargennummer des Produkts eingeben. Lot- und Chargennummern sind auf dem Produktetikett hinter den Wörtern ‘Lot’ oder ‘Batch’ (Lot oder Charge) zu finden.

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Kunden haben sich ebenfalls angesehen

Slide 1 of 9

1 of 9

Scriptaid ≥95%, solid

Sigma-Aldrich

S7817

Scriptaid

LMK235 ≥98% (HPLC)

Sigma-Aldrich

SML1053

LMK235

Tubacin ≥98% (HPLC)

Sigma-Aldrich

SML0065

Tubacin

M344 ≥98% (HPLC), powder

Sigma-Aldrich

M5820

M344

Apicidin ≥98% (HPLC), from microbial

Sigma-Aldrich

A8851

Apicidin

5-Azacytidin ≥98% (HPLC)

Sigma-Aldrich

A2385

5-Azacytidin

EX-527 ≥98% (HPLC)

Sigma-Aldrich

E7034

EX-527

Trichostatin A, Ready Made Solution 5 mM in DMSO, from Streptomyces sp.

Sigma-Aldrich

T1952

Trichostatin A, Ready Made Solution

UNC0638 hydrate ≥98% (HPLC)

Sigma-Aldrich

U4885

UNC0638 hydrate

HoxC5 and miR-615-3p target newly evolved genomic regions to repress hTERT and inhibit tumorigenesis
TingDong Y et al.
Nature Communications, 100 (2018)
Marta Bombardo et al.
Scientific reports, 8(1), 9391-9391 (2018-06-22)
Adult pancreatic acinar cells have the ability to re-enter the cell cycle and proliferate upon injury or tissue loss. Despite this mitotic ability, the extent of acinar proliferation is often limited and unable to completely regenerate the injured tissue or
Heather MacTavish et al.
PloS one, 5(12), e14462-e14462 (2011-02-02)
Histone deacetylase inhibitors (HDI) dampen cellular innate immune response by decreasing interferon production and have been shown to increase the growth of vesicular stomatitis virus and HSV. As attenuated tumour-selective oncolytic vaccinia viruses (VV) are already undergoing clinical evaluation, the
Xuelian Xu et al.
PloS one, 6(2), e17138-e17138 (2011-03-02)
Pediatric acute myeloid leukemia (AML) remains a challenging disease to treat even with intensified cytarabine-based chemotherapy. Histone deacetylases (HDACs) have been reported to be promising therapeutic targets for treating AML. However, HDAC family members that are involved in chemotherapy sensitivities
Ilaria Lepore et al.
PloS one, 8(12), e83018-e83018 (2013-12-19)
Over the past years BARD1 (BRCA1-associated RING domain 1) has been considered as both a BRCA1 (BReast Cancer susceptibility gene 1, early onset) interactor and tumor suppressor gene mutated in breast and ovarian cancers. Despite its role as a stable
Alle zugehörigen Dokumente anzeigen

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.